SCA Pharma to expand production facility in LR, could double workforce of 180
by July 21, 2020 12:29 pm 1,445 views
SCA Pharma, an FDA-registered outsourcing facility, announced Tuesday (July 21) that it will expand its operations in Little Rock.
SCA will invest more than $10 million and potentially double its current workforce of 180 people, the company said. Additionally, the investment will allow SCA Pharma to renovate an existing 42,000-square-foot facility at the Clinton National Airport and construct an additional 20,000-square-foot facility adjacent to the existing facility.
SCA announced last week that it also plans a 40% expansion of its Windsor, Conn., facility.
“We are very pleased that as we continue our geographical expansions in both Arkansas and Connecticut, we can partner with the Arkansas Economic Development Commission (AEDC) and the Little Rock Municipal Airport Commission to solidify and expand the operations of our legacy operations,” said Milton Boyer, CEO of SCA Pharma. “Little Rock has been the foundation that has allowed for our other expansion projects, and this project will bolster that foundation for years to come.”
SCA was founded in Little Rock in 2010. A leading manufacturer of compounded pharmaceuticals, the company said it has experienced significant growth over the past five years.
“Arkansas is committed to nurturing its homegrown companies from seed stage upward,” Gov. Asa Hutchinson said. “We are proud to see the success that SCA Pharma is experiencing and look forward to the products and services being developed here in central Arkansas that will positively impact the lives of people around the country.”
The expansion of both locations will also create the need for technical and highly-skilled jobs for both areas, the company said.
SCA Pharma is a nationally-recognized FDA 503B outsourcing facility specializing in providing high-quality sterile admixture services to hospital pharmacies throughout the U.S.
SCA alleviates common problems health care facilities face such as wasted product, drug shortages, time-consuming processes, compliance issues, staffing costs, and patient safety concerns.